We thought 2021 would be the year the Covid-19 pandemic ended and life returned to normal. Not only did not happen, for those forced to cancel holiday plans for a second year, or for those taken ill by omicron (or as my kids call it, “omicrummy”), 2021 felt uncomfortably similar to 2020. But, in reality, we may be even closer to the end of the pandemic.
For those taken ill by omicron (or as my kids call it, “omicrummy”), 2021 felt uncomfortably similar to 2020.
The first, and best, reason to be optimistic about Covid’s trajectory is the percentage of people who’ve gotten vaccinated. While tens of millions of Americans stubbornly and illogically refuse to get inoculated against a virus that has taken more than 814,000 U.S. lives, 73 percent of all Americans have received at least one dose of a Covid vaccine. For those 12 and above, 84 percent have had at least one shot. Eighty-eight percent of people who are 65 and over, and thus most vulnerable to Covid, are fully vaccinated, and 95 percent have received at least one shot.
Across the globe, more than 8 billion doses have been administered, and 3.8 billion people, just under half of all of humanity, are fully vaccinated. While these numbers need to be higher, that so many people have been vaccinated — in just under a year — is one of the most extraordinary public health accomplishments in human history. It’s a powerful reminder of our ingenuity and capabilities.
Beyond the good news on vaccines, there’s even more good news on the development of treatments for Covid.
Last week, the Food and Drug Administration authorized for emergency use Paxlovid, Pfizer’s antiviral treatment that has been shown to reduce the risk of hospitalization or dying by close to 90 percent among high-risk patients. The agency also authorized the use of molnupiravir, a Merck antiviral.
Dr. William Schaffner, professor of infectious diseases at the Vanderbilt University School of Medicine, told me these treatments can “prevent the evolution of an infection into a serious illness” and that the Pfizer pill, in particular, “looks very exciting.”
However, Schaffner warned, the near-term benefits of these treatments remain “murky” because the “logistics of distribution are complicated.”
The pills are most effective at the first indication of illness, but without adequate home testing, a person may not be able to get a positive result until it’s too late, Schaffner said.
Then there’s this question: “Who does the screening to figure out who is at the greatest risk?” There will also be questions concerning access: where people can get the pills and how much they’ll cost. In addition, health care providers will need to be educated about the treatments and potentially dangerous drug interactions. In Schaffner’s view, the antiviral treatments “will be a game changer once the rules of the game are established.”
What about omicron? Doesn’t that change the trajectory of the pandemic? Ironically, there’s a potential silver lining in this latest variant. Early reports indicate that it is less severe than earlier Covid variants — in particular, delta. So as it spreads through the population, it may make people sick but not lead to more hospitalizations or deaths. If that’s the case, Schaffner said unvaccinated people may get sick — though not fatally — and thus have greater natural immunity to Covid going forward. That would expand the number of people unlikely to get seriously ill from the virus.
“It could,” Schaffner said, “signal the end of the pandemic phase” and move Covid into the realm of illness and nuisance but not death. If that were to occur, with most people being vaccinated or with sufficient immunity, things could return to normal sooner rather than later.








